Doximity's core marketing niche is maturing, with revenue growth decelerating to 7.3% year-over-year in 2027Q1 from 23.2% in 2026Q2, while gross margins have eroded to 84.9% from a peak of 91.6%. The company is investing heavily in AI and sales capacity, drivi...
Price trend, volume and key moving averages
Trailing total returns as of 9/23/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 6, 2026 | $0.29-4.3% vs $0.30 | $157M+3.2% vs $152M |
Q2 2026 May 13, 2026 | $0.26-7.1% vs $0.28 | $145M+0.9% vs $144M |
Q1 2026 Feb 5, 2026 | $0.46+4.5% vs $0.44 | $185M+1.9% vs $182M |
Q4 2025 Nov 6, 2025 | $0.45+18.8% vs $0.38 | $169M+6.7% vs $158M |
AXQ Capital LP grew its stake in shares of Doximity, Inc. (NYSE: DOCS) by 1,354.5% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 177,044 shares of the company's stock after buying an additional 164,872 shares during the period. AXQ
On August 28, 2026, Doximity Inc (DOCS) shares rose 4.5% to a current price of $26.73. This performance occurred amidst a 52-week range of $17.15 to $76.51, ind
On August 27, 2026, Doximity Inc (DOCS) shares rose 3.4% to a current price of $25.59, reflecting a significant shift amidst a 52-week range of $17.15 to $76.51
MedPeer,Inc. (OTCMKTS:MDPEF - Get Free Report) and Doximity (NYSE: DOCS - Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, valuation, risk, dividends and analyst recommendations. Earnings and Valuation This table compares MedPeer,Inc. and Doximity"s gross
Benchmark DOCS against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Doximity, Inc. (DOCS)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $26.51 | $4.96B | 27.05 | 13.05% | 30.4% | 19.28% | — | |
| $30.43 | $6.79B | 59.67 | 59% | -5.51% | -30.03% | — | |
| $230.31 | $165.95B | 165.69 | 35.82% | 10.67% | 3.08% | — | |
| $16.67 | $1.93B | -13.66 | 8.28% | -21.25% | -44% | — | |
| $260.91 | $42.38B | 47.96 | 16.34% | 29.34% | 14% | — | |
| $20.98 | $1.55B | 6.36 | 18.52% | 80.56% | 30.03% | — |
Doximity, Inc. (DOCS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Doximity, Inc. (DOCS) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 6, 2026·SEC
May 13, 2026·SEC
Apr 17, 2026·SEC
Get notified when DOCS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Doximity, Inc. (DOCS) stock FAQ — growth, dividends, profitability & financials explained
Doximity, Inc. (DOCS) reported $655.6M in revenue for fiscal year 2026. This represents a 665% increase from $85.7M in 2019.
Doximity, Inc. (DOCS) grew revenue by 13.1% over the past year. This is steady growth.
Yes, Doximity, Inc. (DOCS) is profitable, generating $167.0M in net income for fiscal year 2026 (30.4% net margin).
Doximity, Inc. (DOCS) has a return on equity (ROE) of 19.3%. This is reasonable for most industries.
Doximity, Inc. (DOCS) generated $299.3M in free cash flow for fiscal year 2026. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
